BioSpace News Archive

ReCode Therapeutics, a clinical-stage genetic medicines company using tissue-specific delivery to power the next wave of mRNA and gene correction therapeutics, announced the publication of a research article in Science.

Xilio Therapeutics, Inc. announced the appointment of Aoife Brennan, M.D., and James Shannon, M.D., to the company’s board of directors.

Voyager Therapeutics, Inc., a biotechnology company dedicated to advancing neurogenetic medicines, announced that the company will participate in fireside chats at the TD Cowen Genetic Medicines & RNA Summit on June 20, 2024, at 1:35 p.m. ET and at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference on June 27, 2024, at 7:00 a.m. ET.

CyanVac LLC, a clinical-stage biotechnology company developing intranasal vaccines using a transformational parainfluenza virus 5 -based vector, announced that it received federal Project NextGen funding to support a comparative Phase 2b study of CVXGA, the company’s PIV5-based vaccine candidate designed to protect against COVID-19.

Vaxart, Inc. announced an underwritten offering of 50,000,000 shares of its common stock at an offering price of $0.80 per share, which is a premium to the last closing price of $0.75 per share.

Innovent Biologics, Inc. announced that clinical data of IBI363 in advanced solid tumors are presented at the 2024 ESMO Virtual Plenary.

Gain Therapeutics, Inc. announced the pricing of an underwritten public offering of 7,116,547 shares of its common stock at a public offering price of $1.35 per share and pre-funded warrants to purchase 1,031,602 shares of common stock in lieu of shares of common stock to certain investors.

Rezolute, Inc. announced the pricing of its previously announced underwritten public offering of an aggregate of 11,250,000 shares of its common stock at an offering price of $4.00 per share, and, to certain investors in lieu of common stock, pre-funded warrants to purchase up to 3,750,000 shares of common stock at an offering price of $3.999 per pre-funded warrant.

Biosplice Therapeutics, Inc., a clinical-stage biotechnology company pioneering first-in-class therapeutics based on small-molecule inhibition of DYRK/CLK kinases, has entered a collaboration with Novo Nordisk to develop drug candidates for the treatment of diabetes.

Protalix BioTherapeutics, Inc. announced that it will host an in-person investor day at the Lotte Palace New York Hotel in New York on Wednesday, June 26, 2024 at 8:30 a.m. Eastern Daylight Time.